-
Evidence-based, evidence-based-the current status of diagnosis and treatment of bone metastases from prostate cancer
Time of Update: 2021-10-01
The PREVAIL study showed that compared with placebo, enzalutamide can significantly prolong the median overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not been chemotherapy before (36 vs 31) Month, HR=0.
-
A quick overview of recent real-world studies of abiraterone acetate——Expert interpretations of Professor Zeng Hao and Professor Li Yonghong
Time of Update: 2021-10-01
Study 1 explored different types of prostate intraductal cancers (IDC-P) subtypes of mCRPC patients respond differently to treatment with abiraterone acetate and docetaxel .
-
The first ICOS inhibitor: new hope for patients with metastatic urothelial cancer
Time of Update: 2021-10-01
Results: As of March 16, 2021, the median age of patients in the single-agent group was 69 years, 92% of patients were male, and 85% of patients had previously received ≥2 line therapy .
-
【Explanation】From simple taste to ascendant: Analysis of the development trend of prostate cancer immunotherapy
Time of Update: 2021-10-01
Cohort B included mCRPC patients who had not undergone chemotherapy, were undergoing androgen deprivation treatment, and had received up to two new anti-androgen therapies in the past to evaluate the efficacy and safety of nivolumab + docetaxel .
-
Express delivery requires only one urine sample, and the innovative liquid biopsy is more than 90% accurate in predicting prostate cancer!
Time of Update: 2021-10-01
▎The content team editor of WuXi AppTec recently, the data released by miR Scientific at the annual meeting of the American Urological Association (AUA) showed that its technology of using urine to detect prostate cancer can accurately detect prostate cancer at the molecular level and its risks Classification .
-
A breakthrough in phenotypic precision medicine: radioligand therapy improves overall survival in metastatic castration-resistant prostate cancer
Time of Update: 2021-10-01
Han Xingmin*, Wang Ruihua, Xu Shasha Department of Nuclear Medicine, the First Affiliated Hospital of Zhengzhou University; Henan Provincial Key Laboratory of Molecular Imaging Medicine* Corresponding author Prostate cancer has become the tumor with the highest incidence in the urinary system, and the incidence of male malignant tumors in 2020 The rate and death rate are ranked 2nd and 5th respectively [1] .
-
Professor Yang Bin: Preoperative neoadjuvant treatment of prostate cancer lined up
Time of Update: 2021-10-01
analyzed 14 studies on neoadjuvant endocrine therapy from 1966 to 2007, and the results showed that it can reduce the positive rate of resection margins, the tumor stage of T3 patients, and the positive rate of lymph nodes, but the OS and tumor-specific survival rate (CSS) No improvement; Kumar et al.
-
Tribute to the founding of the party for a hundred years!
Time of Update: 2021-08-25
, CDE included AstraZeneca olaparib tablets for prostate cancer indications as a priority review, as a single agent for the treatment of BRCA1/2 mutations (germline and/or somatic cell lines) that appeared after previous treatment with new hormone drugs Adult patients with progressive mCRPC .
-
CR reached within 6 weeks of treatment, and the total diameter of the target lesion was reduced by nearly 78%. MRG002 brings new survival hope for patients with advanced HER2-positive urothelial carcinoma
Time of Update: 2021-08-25
Among them, an open, single-arm, multi-center phase II clinical trial of MRG002 for the treatment of HER2-positive unresectable locally advanced or metastatic urothelial carcinoma after at least first-line systemic chemotherapy was launched in February 2021 .
-
【Weekly Doctors】Asymptomatic bacteriuria in patients with long-term indwelling catheterization, what is the most appropriate treatment?
Time of Update: 2021-08-19
While answering the questions, please leave a message with your answers and diagnosis and treatment ideas to us .
The answer will be announced tomorrow, and we will see you or leave!
-
What is the most appropriate treatment for asymptomatic bacteriuria in patients with long-term indwelling catheterization?
Time of Update: 2021-08-18
Knowledge expansion Asymptomatic bacteriuria is seen in almost all patients with long-term indwelling catheters, even if urinalysis shows pyuria, no treatment is needed .
Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America.
-
Frequent and painful urination recurring after antibiotic treatment, why not combine estrogen therapy?
Time of Update: 2021-08-12
In the study [3], in the treatment of genitourinary tract infections in postmenopausal women, oral fluoroquinolone drugs combined with estriol cream were used: estrogen cream 0.
Clinical study of low-dose estrogen in the treatment of postmenopausal women with recurrent urinary tract infections[J ].
-
Consensus Points of Chinese Experts on Prostate Cancer Screening (2021 Edition)
Time of Update: 2021-08-12
"Early screening, early diagnosis, and early treatment" is one of the effective methods to improve the 5-year survival rate of cancer patients .
Therefore, screening, early diagnosis and treatment of high-risk groups are effective means to improve the overall survival rate of Chinese prostate cancer patients .
-
Express treatment of bladder cancer, "first-in-class" antibody-conjugated drugs expand indications
Time of Update: 2021-08-10
▎The content team editor of WuXi AppTec today, Seagen and Astellas jointly announced that the US FDA has approved the company’s antibody-conjugated drug (ADC) Padcev (enfortumab vedotin-ejfv) for extended indications for the treatment of previous Patients with locally advanced or metastatic urothelial cancer who have received at least one pre-treatment, but are not suitable for receiving cisplatin-containing chemotherapy .
-
Apartamide + ADT in the treatment of mHSPC has a rapid onset and full strength in classic cases
Time of Update: 2021-08-10
Bilateral pelvic lymph node biopsy results under 3D laparoscopic clinical diagnosis: prostate cancer with multiple metastases throughout the body (cT3bN1M1b) adrenal adenoma (left side) renal cyst (bilateral) lung bullae and emphysema (bilateral) cavity Reflux esophagitis with intermittent cerebral infarction on March 22, 2021, adjust the treatment plan to apatamide 240mg once/day orally + goserelin 10.
-
【2021 EAU】Research progress on apatamide
Time of Update: 2021-08-10
. Abstract P0845 The results of the high and low tumor burden subgroups of the final analysis of the TITAN study of apatamide [1] The TITAN study is a multi-center, randomized, double-blind, controlled, prospective global phase III clinical study aimed at exploring apatamide +ADT and placebo (PBO) + ADT for the efficacy and safety of patients with metastatic hormone-sensitive prostate cancer (mHSPC) .
-
Urinary tumor-related drugs: the 2021 version of the drug catalog of the super drug insert
Time of Update: 2021-08-09
Hematology Oncology Committee of Chinese Anti-Cancer Association, "Bladder Cancer Diagnosis and Treatment Standards" (2018 Edition) micromedex classification: Effectiveness Class Ⅱa, Recommendation Class Ⅱb, Evidence Strength Category B Nivolumab adaptation Syndrome: Intermediate to high-risk advanced renal cell carcinoma (combined with ipilimumab or monotherapy for patients who have received anti-angiogenesis therapy) Specific usage: combined with ipilimumab: intravenous infusion of 3 mg·kg-1 within 30 minutes , And then give Ipilimumab 1 mg·kg-1 on the same day, 4 doses every 3 weeks .
-
"Precision Diagnosis and Treatment" helps decision-making in the treatment of prostate cancer, PROfound research opens up the era of targeting——Professor Ye Dingwei talks about guidelines update
Time of Update: 2021-08-09
Based on the results of the TOPARP-A study of olaparib, the 2020 EAU guidelines recommend the use of PARP inhibitors for mCRPC patients after one endocrine therapy and docetaxel treatment .
-
"Sex" blessing is related to these drugs!
Time of Update: 2021-08-08
Many studies have shown that diuretics are the antihypertensive drugs that have the greatest impact on male sexual function, including decreased libido, erectile dysfunction, and difficulty ejaculation .
Long-term use of spironolactone can cause decreased male libido and erectile dysfunction .
-
Experts interpret the research progress of ASCO advanced urothelial cancer treatment in 2021
Time of Update: 2021-06-22
The ASCO meeting reported the five-year follow-up update results of the second-line immunotherapy KEYNOTE045 study of advanced urothelial cancer .
The results of the study showed that the ORR of feladilimab patients (PD-1 monoclonal antibody progression) was 7%, the disease control rate (DCR) was 22%, and the median OS was 14.